SBIR Phase I: Multiwavelength Laser Spectroscopy System for Non-Invasive Bio-Assay

这个小型企业创新研究第一阶段的研究项目将展示一种可携带、可穿戴的近红外、多波长光谱单元光源的可行性。这将使便携式、非侵入性的血液光谱通过用紧凑、高效的半导体激光器光源取代钨丝光源实现。将展示一种具有成本效益的可扩展激光技术平台，该平台可访问临床相关的1350nm至2450nm波长范围，其中包括用于检测血液乙醇、尿素或葡萄糖的最佳指纹范围。这将产生一个强大而高效的光源/光谱平台，这将使基于光学的人类健康非侵入性监测系统的性能得到显著提高，尺寸减小。该项目的商业应用将在糖尿病的管理和治疗中得到应用。糖尿病是一种影响数百万美国人的疾病。众所周知，这种疾病的许多慢性损害是由于长期监测血糖水平不足造成的。实时监测和干预血糖水平变化的强大策略将对这数百万人的生活质量产生革命性的影响，并对全球数百万人的生活质量产生革命性的影响。

This Small Business Innovation Research Phase I research project will demonstrate the feasibility of a light source for a portable and wearable near infrared, multi-wavelength spectroscopy unit. This will enable portable, non-invasive blood spectroscopy by the displacement of tungsten filament based light sources with compact, efficient light sources based on semiconductor lasers. A laser technology platform that is scalable in a cost effective manner to access the clinically relevant 1350nm to 2450nm wavelength range, which includes an optimal fingerprint range for the sensing of blood ethanol, urea or glucose, will be demonstrated. This will result in a robust and efficient light source / spectroscopy platform that will enable dramatic performance improvements and size reductions in systems for optically based non-invasive monitoring of human health.The commercial application of this project will in the management and treatment of diabetes. Diabetes is a disease that affects millions of Americans. It is well known that much of the chronic damage from this disease results from inadequate monitoring of blood sugar levels over time. A robust strategy for real time monitoring and intervention in glucose level variation will have a revolutionary impact on the quality of life for these millions, and millions more worldwide.